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In patients with Parkinson’s disease (PD), the molecularly misfolded form of 𝛼-synuclein was recently identified in cutaneous
autonomic nerve fibers which displayed increased accumulation even in early disease stages. However, the underlying mechanisms
of synucleinopathic nerve damage and its implication for brain pathology in later life remain to be elucidated. To date, specific
diagnostic tools to evaluate small fiber pathology and to discriminate neurodegenerative proteinopathies are rare. Recently,
research has indicated that deposition of 𝛼-synuclein in cutaneous nerve fibers quantified via immunohistochemistry in superficial
skin biopsies might be a valid marker of PD which could facilitate early diagnosis and monitoring of disease progression.
However, lack of standardization of techniques to quantify neural 𝛼-synuclein deposition limits their utility in clinical practice.
Additional challenges include the identification of potential distinct morphological patterns of intraneural 𝛼-synuclein deposition
among synucleinopathies to facilitate diagnostic discrimination and determining the degree to which structural damage relates
to dysfunction of nerve fibers targeted by 𝛼-synuclein. Answering these questions might improve our understanding of the
pathophysiological role of small fiber neuropathy in Parkinson’s disease, help identify new treatment targets, and facilitate
assessment of response to neuroprotective treatment.
1. Introduction
Clinical management of Parkinson’s disease (PD) has under-
gone substantial innovations that comprise both diagnostic
assessment and pharmacotherapy. However, the disease still
poses a clinical challenge due its high prevalence and our
restricted understanding of its underlying pathology.The lat-
ter explains why, to date, no causative treatment is available.
Moreover, the range of tools to detect early and premotor
pathology is limited. This may prevent timely initiation of
dopaminergic treatment and thereby improvement of quality
of life [1]. In order to provide individualized treatment, it
is also important to differentiate PD from atypical Parkin-
sonism syndromes, a problem which is difficult to solve in
clinical practice, particularly in early and prodromal disease
stages. In an effort to address these challenges research
has focused on identifying reliable disease markers. The
molecularly misfolded form of the protein 𝛼-synuclein has
recently been identified in autonomic nerve fibers of the skin.
In these small lightly myelinated and unmyelinated nerve
fibers, 𝛼-synuclein deposits are present even in the early
stages of PD as demonstrated by an analysis of skin biopsies
immunohistochemically costained for 𝛼-synuclein and nerve
fibers [2]. This technique has enabled, for the first time,
assessment of synucleinopathic changes in the peripheral
nervous system and has been reproduced or modified in
several research studies in patients with PD [3–5]. However,
the mechanisms whereby synucleinopathic nerve damage
relates to central neurodegeneration in later life and how it
might play a causative role in PD remain unknown.
Immunohistochemical detection of intraneural 𝛼-
synuclein deposition in epidermal structures innervated
by autonomic small fibers offers a novel tool to study
pathology in PD and might provide a valid biomarker of
PD as suggested by a number of well-designed experimental
studies [2, 6, 7]. We reviewed the current literature on
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detection of 𝛼-synuclein in skin biopsies in order to
approach the question whether this technique might be
a useful supplement to other clinical diagnostic tests in
patients with possible Parkinson’s disease.
2. Synucleinopathic Small Fiber Neuropathy:
What Do We Know?
The epidermal layer of the skin is innervated by small fibers,
which comprise unmyelinated C-fibers and thinly myeli-
nated A-delta fibers [8]. A structural analysis of cutaneous
denervation in a population of PD patients has displayed
a link between 𝛼-synuclein deposition in autonomic small
fibers and severity of clinical symptoms related to autonomic
dysregulation such as orthostatic hypotension or sweating
disturbances, indicating the usefulness of skin pathology
as potentially valid disease marker [2]. Additional analyses
within the same cohort have shown that, in patients with PD,
the amount of 𝛼-synuclein positive nerve fibers normalized
to total intraepidermal nerve fiber density (𝛼-synuclein ratio)
is enhanced in both sympathetic cholinergic (sweat gland
innervating) and sympathetic adrenergic (pilomotor muscle
innervating) nerve fibers. Interestingly, higher 𝛼-synuclein
ratios were also associated with higher severity of motor
symptoms in this study. However, if and to what degree
this positive correlation might point to a direct causative
association between peripheral autonomic and central motor
pathology remains unknown. An indirect indication toward
such an association has been provided by the similar mor-
phology ofmisfolded𝛼-synuclein accumulation in cutaneous
small fibers and in neurites in the substantia nigra. In both
structures, 𝛼-synuclein staining showed an irregular line
following the course of the neural structure (small fiber and
neurite, resp.) [6].
Subsequent investigations have corroborated these obser-
vations and provided Class III evidence. An analysis of skin
biopsies detected 𝛼-synuclein aggregation in skin samples
from all 21 patients with PD but no aggregation in any
of the samples from the 20 individuals with Parkinsonism
syndromes (i.e., vascular Parkinsonism, tauopathies, and
pathogenic Parkin mutations) [9]. The study was limited by
the lack of quantitative analysis of intraneural 𝛼-synuclein
load and the absence of normalization to intraepidermal
nerve fiber loss. Its strength, however, was the use of an
antibody targeting the presumably pathogenic misfolded
(phosphorylated) form of 𝛼-synuclein. Another study used
skin biopsies with quantification of 𝛼-synuclein deposition
in pilomotor and sudomotor nerve fibers normalized to
the overall intraepidermal nerve fiber density. This analysis
demonstrated >90% sensitivity and >90% specificity to dis-
tinguish PDpatients from control individuals via𝛼-synuclein
ratios in a prospective longitudinal study [7].
3. Cutaneous 𝛼-Synuclein in Prodromal
Disease Stages/Possible PD
Since phosphorylated 𝛼-synuclein is present in patients in
PD even in the early stages of the disease (Hoehn and Yahr I
and II), research has recently addressed the question whether
this pathology might also be present in the premotor stages.
Skin nerve pathology was assessed in individuals with REM
sleep behaviour disorder (RBD) as these patients display a
substantially increased risk of developing PD in later life.The
likelihood of developing PDwas further determined based on
additional predictors such as reduced dopamine transporter
binding in FP-CIT-SPECT and anosmia. Consistent associa-
tions between 𝛼-synuclein deposition and presence of RBD,
dopamine transporter insufficiency, and olfactory dysfunc-
tionwere observed [10]. In line with this observation, a recent
study in 12 patients with polysomnographically confirmed
RBD and 55 sex- and age-matched healthy controls has pro-
vided Class III evidence that intraneural deposition of phos-
phorylated 𝛼-synuclein is present in patients with RBD [11].
These findings indicate that cutaneous phosphorylated 𝛼-
synuclein might help to identify individuals with prodromal
Parkinson’s disease which might be particularly important
in the development of novel disease modifying strategies.
Although promising, these results need to be considered with
care since only 18 patients with RBD were included in the
analyses. Longitudinal data is warranted to assess whether
phosphorylated𝛼-synucleinmight indeed predict conversion
from RBD into PD. Additionally, experiments need to be
repeated in a larger study population to allow evaluation of
external validity.
4. Distinguishing Synucleinopathies
and Nonsynucleinopathic
Neurodegenerative Disorders
Among the potential clinical applications of cutaneous 𝛼-
synuclein assessment, its capacity to differentiate patients
with PD from patients with other synucleinopathies based on
distinct patterns of neural skin pathology has been discussed.
In a cross-sectional investigation, 62% of skin biopsies from
PD patients showed cutaneous 𝛼-synuclein, whereas only
7% of skin biopsies from patients with atypical Parkinson
syndrome were positive for 𝛼-synuclein. However, this study
considered 𝛼-synuclein inclusions in the epidermis and in
pilosebaceous units but did not specifically assess intraneural
accumulation [12]. Further limitations include a relative
small sample size (34 subjects with PD, 33 patients with
atypical Parkinson syndrome, and 20 control individuals) and
heterogeneity within the group of atypical Parkinson syn-
drome which included synucleinopathies, such as dementia
with Lewy bodies (DLB), multisystem atrophy (MSA), and
tauopathies such as Alzheimer’s disease (AD) and progressive
supranuclear palsy (PSP), possibly jeopardizing interpretabil-
ity.
Synucleinopathic neurodegenerative disorders have been
hypothesized to display distinct patterns of 𝛼-synuclein
aggregates in the central and the peripheral nervous system.
Contrarily to PD, MSA has been described as isolated
disorder of the central nerve system with accumulation
of phosphorylated 𝛼-synuclein limited to brain tissue and
preganglionic neurons [13]. In line with this assumption,
the examination of cutaneous autonomic adrenergic nerve
fibers revealed no deposition of phosphorylated 𝛼-synuclein
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in MSA patients [14]. However, an immunohistochemical
analysis of cutaneous somatosensory fibers has unexpectedly
revealed enhanced 𝛼-synuclein deposition in sensory fibers
in 67% of MSA patients, whereas a similar fraction of PD
patients showed 𝛼-synuclein aggregation in autonomic small
fibers [15]. In line with this observation, sudomotor dener-
vation has been reported in patients with MSA indicating
postganglionic impairment of the sympathetic nervous sys-
tem which may contribute alongside degeneration of central
autonomic structures to dysautonomia in these patients [16].
These observationsmodify the current conception ofMSA as
a solely or predominant disease of the central nervous system.
Further insights into the pathophysiology of synucle-
inopathies have been provided by Donadio et al. who found
length-dependent somatic and autonomic small fiber dam-
age, both in patients with PD and in those with pure auto-
nomic failure (PAF). The degree of cutaneous denervation
was associated with the amount of 𝛼-synuclein accumula-
tion [17]. Interestingly, differences in patterns of cutaneous
denervation and 𝛼-synuclein accumulation appear not to
be related to patterns of autonomic dysfunction including
cardiovascular dysfunction detected by head-up tilt-test and
sympathetic nerve dysfunction characterized by microneu-
rography [18]. These discrepancies between structural and
functional changes of the autonomic nervous system among
synucleinopathies underscore our still limited understanding
of the underlying pathophysiological mechanisms [19]. How-
ever, it also implies that defining disease specific patterns of
𝛼-synuclein pathology might improve early diagnosis, help
monitoring synucleinopathies in clinical practice, and facili-
tate assessment of response to disease modifying treatment.
In order to improve our understanding of the direct effects of
𝛼-synuclein on skin nerves, to what extent structural changes
of these nerves are related to their functional impairment
of these fibers ought to be investigated. This highlights
the need for detailed characterization of skin denervation
patterns, including quantitative examinations of intraneural
𝛼-synuclein deposition beyond autonomic fibers in follow-
ing investigations. Further research is needed to provide a
detailed characterization of 𝛼-synuclein accumulation pat-
terns among somatic and autonomic small nerve fibers in
large populations of affected patients with synucleinopathies
such as PD and MSA. This should also include longitudinal
studies to characterize progression of neuropathy.
5. How to Obtain and Handle Skin Biopsies
The structural assessment of autonomic skin innervation is
still on an experimental level. Both techniques to obtain
and handle biopsies and procedures to process and ana-
lyze specimens require standardization. Proposed protocols
include immunohistochemical analysis of phosphorylated
𝛼-synuclein or the 𝛼-synuclein/PGP-ratio in skin punch
biopsies obtained from varying skin areas such as the dorsal
forearms or the lower legs. Commonly, three-millimeter
biopsies are obtained following local anesthesia with lido-
caine (see Figure 1).
Biopsy specimens are then fixed (e.g., in Zamboni solu-
tion) and cryoprotected. Frozen tissue blocks are cut into
sections using a microtome. Parameters and techniques
vary among published protocols. Multiple costains with 𝛼-
synuclein, phosphorylated 𝛼-synuclein, protein gene product
(PGP) 9.5 (nonspecific nerve fiber marker), tyrosine hydrox-
ylase (TH, adrenergic fiber marker), and vasoactive peptide
(VIP, cholinergic fiber marker) allow analyses of 𝛼-synuclein
deposits in different types of small fibers. To determine
intraepidermal nerve fiber density PGP 9.5-positive fibers
in skin biopsies should be counted in blinded fashion with
results expressed as number of fibers crossing the dermal-
epidermal junction per millimeter. Sweat glands and pilomo-
tor muscles can be imaged and nerve fiber densities quan-
tified, preferably in a blinded fashion. In sweat glands, the
number of nerve fibers intersecting the circles within the area
of interest is counted and reported as the percentage of circles
with nerve fiber crossing. Similarly, in pilomotor muscles,
the average number of nerve fibers intersecting horizontal
lines across the width of the pilomotor muscle in 3 𝜇m thick
confocal images is reported in fibers/mm. Techniques to
assess 𝛼-synuclein deposition in vasomotor fibers are still
being designed. Alpha-synuclein/nerve fiber density ratios
can then be calculated for (a) epidermis, (b) sweat glands, and
(c) pilomotor muscles [2, 7, 17]. Other approaches include
advanced morphological qualitative analyses of 𝛼-synuclein
deposition [6, 10].
6. Functional Assessment of Cutaneous
Autonomic Denervation
Dysfunction of autonomic small fibers is of clinical rel-
evance. In general, autonomic neuropathies constitute a
group of conditions in which the small, unmyelinated, and
lightly myelinated autonomic nerve fibers display structural
and functional impairment. Autonomic symptoms involve
the cardiovascular, urogenital, gastrointestinal, sudomotor,
and pupillomotor systems. Clinical manifestations range
from bladder dysfunction over orthostatic hypotension to
dyshidrosis, erectile dysfunction, and obstipation. Although
diabetes is the most prevalent cause of autonomic fiber
dysfunction in more developed countries, targeted fiber
damage can also occur in various systemic diseases such
as amyloidosis, paraneoplastic syndromes, and infectious
diseases and has been shown to be targeted by peripheral
synucleinopathies such as PD [3, 18–20].
While structural assessment of 𝛼-synuclein pathology
in skin biopsies is the most direct test of cutaneous 𝛼-
synuclein pathology, evaluation of small fiber dysfunction
resulting from intraneural 𝛼-synuclein deposition might be
of additional diagnostic value. This rationale is indirectly
supported by a strong correlation between 𝛼-synuclein load
in cutaneous small fibers and measures of cardiovascular
sympathetic and parasympathetic function, although these
tests are composite measures of central and peripheral auto-
nomic function and do not specifically capture small fiber
integrity [2]. On these composite assessments, cutaneous 𝛼-
synuclein deposits can be present even in PDpatients without
autonomic dysfunction. This raises the question if more
specific tests of functional integrity of small autonomic fibers
might be necessary in the assessment of cutaneous autonomic
4 Parkinson’s Disease
Alpha-synuclein antibody
Skin biopsy
Sudomotor nerve fiber (cholinergic)
Sweat gland
Epidermis
Dermis
Specimen
Figure 1: Obtaining a skin biopsy containing a sweat gland and staining of sudomotor nerve fibers. A punch biopsy is obtained and stained
using immunohistochemical antibodies for 𝛼-synuclein (e.g., anti-phosphorylated 𝛼-synuclein antibody) and nerve fibers (anti-protein gene
product 9.5 antibody). Additional costainingwith the cholinergicmarker vasoactive intestinal peptide can be performed to specifically identify
𝛼-synuclein deposits in cholinergic sudomotor fibers. Figure designed by Dr. Siepmann and Dr. Illigens.
denervation compared to current cardiovascular tests. In fact,
functional evaluation of autonomic cutaneous small fibers
is of growing importance in the assessment of autonomic
neuropathy [20]. A recent study has shown that pilomotor
nerve fibers display functional impairment in early stages of
PD which correlated with severity of autonomic symptoms
[21]. However, skin biopsies have not been obtained in this
study. Therefore, it remains speculative whether pilomo-
tor dysfunction relates to 𝛼-synuclein deposition in these
nerve fibers. It is however noteworthy that, among types
of autonomic small fibers, pilomotor nerves displayed the
highest concentration of intraneural 𝛼-synuclein, supporting
the potential usefulness of pilomotor function assessment in
the detection of early disease related changes [2].
Assessment of autonomic cutaneous small fiber func-
tion is based on quantification of axon reflex responses.
Autonomic skin nerve fibers respond to mechanical, phys-
ical, and chemical stimuli with an axon reflex-mediated
response. Local stimulation of the cutaneous vasomotor
(blood vessel innervating) fibers by iontophoretic application
of acetylcholine evokes orthodromic conduction of an action
potential which then reaches an axon branch point. From this
branch point, the potential is conducted antidromically to
adjacent cutaneous blood vessels. These vessels are located
in an “indirect” area surrounding the skin area where the
axon reflex inducing stimulus is applied. There, activated
vasomotor small fibers release vasoactive substances such
as substance P and calcitonin gene related peptide to cause
vasodilation and plasma extravasation [22] (Figure 2). This
response can be quantified by laser Doppler assessment of
blood flow increase in the indirect skin region [23, 24].
Similarly, functional integrity of sudomotor nerve fibers
can be examined via imaging-based quantification of axon
reflex responsivity to cholinergic stimulation (adrenergic
stimulation in pilomotor fibers, resp.) [22, 25]. In addition
to pilomotor dysfunction, sudomotor axon reflex responsive-
ness was shown to be reduced in PD [26]. Nevertheless, the
degree of association between functional impairment and
structural deterioration of the cutaneous small fibers has
not yet been elucidated. Forthcoming such considerations,
the reproducibility and external validity of quantitative tests
of autonomic sudomotor and pilomotor functions in the
evaluation of PD patients and its association with the 𝛼-
synuclein load are currently being investigated in an ongoing
longitudinal controlled multicenter trial [19].
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Figure 2: Illustration of the vasomotor axon reflex. Iontophoresis of acetylcholine induces vasodilation in the “direct” skin region of
application via receptor activation. Consequently, an action potential emerges in the afferent nerve innervating this vessel. This potential
travels in an orthodromic fashion to an axonal branch point where it switches to another vasomotor fiber. Upon antidromic conduction, the
action potential reaches terminal nerve endings adjacent to a neighboring population of blood vessels. From these terminals, vasoactive
substances are released to cause “indirect” vasodilation in a skin region which is surrounding the region of iontophoresis. Consecutive
enhancement of blood flow relates to functional integrity of the stimulated vasomotor nerve fiber. Similarly, the axon reflex can be evoked in
sympathetic adrenergic pilomotor and sympathetic cholinergic sudomotor fibers. Figure designed by Dr. Siepmann and Dr. Illigens.
7. Limitations and Challenges
While growing evidence emphasizes the diagnostic value
of the assessment of 𝛼-synuclein pathology in PD, most
of the available data is restricted to the detection of 𝛼-
synuclein positive skin nerve fibers. Only few studies provide
quantitative data on the extent of 𝛼-synuclein accumulation
in sudomotor and pilomotor nerve fibers [2, 4]. Additionally,
most of the available date is originated from single center
studies and lack independent blinded evaluation.
Alpha-synuclein load in cutaneous small fibers might be
a valid biomarker for PD. However, several limitations will
have to be addressed to allow its broad clinical application.
First, consensus on the most accurate method of immuno-
histochemical staining and evaluation is needed in order
to provide uniform data and determine clinical standards.
Heterogeneous methods have been described including (1)
the 𝛼-synuclein ratio: normalization of the total 𝛼-synuclein
load to loss of intraepidermal nerve fibers, controlling for
neural damage due to other causes, (2) employment of an
antibody selective for the assumed pathological form of 𝛼-
synuclein (phosphorylated 𝛼-synuclein), and (3) quantifica-
tion of native 𝛼-synuclein without specificity for the patho-
logical form or normalization to fiber loss [2, 7, 14]. While
normalization to loss of intraepidermal nerve fibers and
use of phosphorylated 𝛼-synuclein specific antibodies seem
superior over native 𝛼-synuclein quantification, the optimal
evaluation method remains to be determined. Second,
𝛼-synuclein aggregates were reported in distinct subtypes of
skin autonomic fibers, comprising pilomotor and sudomotor
fibers. However, which fiber type represents the most accu-
rate diagnostic target needs to be answered and potential
pathology in vasomotor fibers needs to be unveiled. Although
two investigations assessing 𝛼-synuclein damage normal-
ized to intraepidermal nerve fiber density reported most
pronounced damage in pilomotor nerve fibers, potentially
indicating high diagnostic value of this type of autonomic
small fibers, independent replication of these observations is
still warranted [2, 7]. Third, longitudinal multicenter studies
in PD and other synucleinopathies that relate cumulative
nerve fiber damage over time to progression of clinical
symptoms are still lacking. Such studies are also necessary to
confirm external validity of the applied techniques. Fourth,
the influence of dopaminergic and neuroprotective treatment
on the progression of autonomic synucleinopathic neuropa-
thy needs to be elucidated [27]. Lastly, while immunohisto-
chemical quantification of 𝛼-synuclein burden in small fibers
reflects structural pathology, its implication on functional
nerve fiber integrity is unknown.
8. Conclusion
Accumulating evidence supports an important pathogenic
role of deposition of 𝛼-synuclein in cutaneous small nerve
fibers in PD which seems to contribute even to development
of the disease in its premotor stages. Quantitative analysis
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of this pathology in skin biopsies might facilitate early
diagnostic discrimination among synucleinopathies, disease
monitoring, and evaluation of response to neuroprotective
treatment. Further research is needed to standardize evalu-
ation techniques, characterize progression of pathology, and
unveil the relation between functional and structural damage
to small nerve fibers caused by 𝛼-synuclein accumulation,
which might eventually answer the question whether we
should perform skin biopsies routinely in patients suspected
of having PD.
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